Guillain-Barre Syndrome - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Guillain-Barre Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Guillain-Barre Syndrome - Pipeline Review, H2 2015', provides an overview of the Guillain-Barre Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Guillain-Barre Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Guillain-Barre Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Guillain-Barre Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Guillain-Barre Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Guillain-Barre Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Guillain-Barre Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Guillain-Barre Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Guillain-Barre Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Guillain-Barre Syndrome - Overview 7
Pipeline Products for Guillain-Barre Syndrome - Comparative Analysis 8
Guillain-Barre Syndrome - Therapeutics under Development by Companies 9
Guillain-Barre Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Guillain-Barre Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Guillain-Barre Syndrome - Products under Development by Companies 14
Guillain-Barre Syndrome - Products under Investigation by Universities/Institutes 15
Guillain-Barre Syndrome - Companies Involved in Therapeutics Development 16
Akari Therapeutics, Plc 16
Alexion Pharmaceuticals, Inc. 17
Takeda Pharmaceutical Company Limited 18
Guillain-Barre Syndrome - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Coversin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
eculizumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
immune globulin (human) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
immune globulin (human) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Guillain-Barre Syndrome - Recent Pipeline Updates 37
Guillain-Barre Syndrome - Dormant Projects 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Number of Products under Development for Guillain-Barre Syndrome, H2 2015 7
Number of Products under Development for Guillain-Barre Syndrome - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Guillain-Barre Syndrome - Pipeline by Akari Therapeutics, Plc, H2 2015 16
Guillain-Barre Syndrome - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015 17
Guillain-Barre Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Guillain-Barre Syndrome Therapeutics - Recent Pipeline Updates, H2 2015 37
Guillain-Barre Syndrome - Dormant Projects, H2 2015 44